352 related articles for article (PubMed ID: 2025952)
1. Terminal complement complexes and C1/C1 inhibitor complexes in rheumatoid arthritis and other arthritic conditions.
Oleesky DA; Daniels RH; Williams BD; Amos N; Morgan BP
Clin Exp Immunol; 1991 May; 84(2):250-5. PubMed ID: 2025952
[TBL] [Abstract][Full Text] [Related]
2. Trimer and tetramer complexes containing C1 esterase inhibitor, C1r and C1s, in serum and synovial fluid of patients with rheumatic disease.
Laurell AB; Mårtensson U; Sjöholm AG
J Immunol Methods; 1990 May; 129(1):55-61. PubMed ID: 2338498
[TBL] [Abstract][Full Text] [Related]
3. C1 inactivator-C1s complexes in inflammatory joint disease.
Inman RD; Harpel PC
Clin Exp Immunol; 1983 Sep; 53(3):521-8. PubMed ID: 6604603
[TBL] [Abstract][Full Text] [Related]
4. Measurement of complement activation products in patients with chronic rheumatic diseases.
Auda G; Holme ER; Davidson JE; Zoma A; Veitch J; Whaley K
Rheumatol Int; 1990; 10(5):185-9. PubMed ID: 2075370
[TBL] [Abstract][Full Text] [Related]
5. C1 activation, with C1q in excess of functional C1 in synovial fluid from patients with rheumatoid arthritis.
Sjöholm AG; Berglund K; Johnson U; Laurell AB; Sturfelt G
Int Arch Allergy Appl Immunol; 1986; 79(2):113-9. PubMed ID: 3484727
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of complement-mediated solubilization of antigen-antibody complexes by sera from patients with rheumatoid arthritis.
Naama JK; Mitchell WS; Whaley K
Clin Exp Immunol; 1983 Nov; 54(2):429-38. PubMed ID: 6652966
[TBL] [Abstract][Full Text] [Related]
7. Lack of activation of C1, despite circulating immune complexes detected by two C1q methods, in patients with rheumatoid arthritis.
Hack CE; Eerenberg-Belmer AJ; Lim UG; Haverman J; Aalberse RC
Arthritis Rheum; 1984 Jan; 27(1):40-8. PubMed ID: 6318777
[TBL] [Abstract][Full Text] [Related]
8. Terminal complement complex in synovial tissue from patients affected by rheumatoid arthritis, osteoarthritis and acute joint trauma.
Corvetta A; Pomponio G; Rinaldi N; Luchetti MM; Di Loreto C; Stramazzotti D
Clin Exp Rheumatol; 1992; 10(5):433-8. PubMed ID: 1458695
[TBL] [Abstract][Full Text] [Related]
9. C1 activation and dissociation in disease.
Laurell AB; Mårtensson U; Sjöholm AG
Immunol Lett; 1987 Feb; 14(3):249-53. PubMed ID: 3032782
[TBL] [Abstract][Full Text] [Related]
10. Circulating complement breakdown products in patients with rheumatoid arthritis. Correlation between plasma C3d, circulating immune complexes, and clinical activity.
Nydegger UE; Zubler RH; Gabay R; Joliat G; Karagevrekis CH; Lambert PH; Miescher PA
J Clin Invest; 1977 May; 59(5):862-8. PubMed ID: 853126
[TBL] [Abstract][Full Text] [Related]
11. Interactions of complement with the red-cell membrane.
Rosse WF
Semin Hematol; 1979 Apr; 16(2):128-39. PubMed ID: 384519
[TBL] [Abstract][Full Text] [Related]
12. A solid-phase antibody capture assay for the measurement of C1-inhibitor consumption in vivo.
Wallace EM; Feighery C; Jackson J
Scand J Clin Lab Invest; 1996 Feb; 56(1):1-9. PubMed ID: 8850166
[TBL] [Abstract][Full Text] [Related]
13. Complement activation, circulating C1q binding substances and inflammatory activity in rheumatoid arthritis: relations and changes on suppression of inflammation.
Berglund K; Laurell AB; Nived O; Sjoholm AG; Sturfelt G
J Clin Lab Immunol; 1980 Jul; 4(1):7-14. PubMed ID: 7463476
[TBL] [Abstract][Full Text] [Related]
14. [Synovial level of interleukin 1 and C3a in chronic polyarthritis, psoriatic arthritis and activated arthritis].
Hermann E; Vogt P; Hagmann W; Dunky A; Müller W
Z Rheumatol; 1988; 47(1):20-5. PubMed ID: 3259355
[TBL] [Abstract][Full Text] [Related]
15. Levels of SC5b--9 complement complex in plasma and synovial fluid of patients with rheumatic disease.
Rus V; Malide D; Boloşiu HD; Parasca I; Duţu AL
Med Interne; 1990; 28(4):305-10. PubMed ID: 2100875
[TBL] [Abstract][Full Text] [Related]
16. Complement activation in seropositive and seronegative rheumatoid arthritis. 125I-C1q binding capacity and complement breakdown products in serum and synovial fluid.
Lambert PH; Nydegger UE; Perrin LH; McCormic J; Fehr K; Miescher PA
Rheumatology; 1975; 6():52-9. PubMed ID: 1202608
[TBL] [Abstract][Full Text] [Related]
17. Synovial fluid levels of anti-cyclic citrullinated peptide antibodies and IgA rheumatoid factor in rheumatoid arthritis, psoriatic arthritis, and osteoarthritis.
Caspi D; Anouk M; Golan I; Paran D; Kaufman I; Wigler I; Levartovsky D; Litinsky I; Elkayam O
Arthritis Rheum; 2006 Feb; 55(1):53-6. PubMed ID: 16463412
[TBL] [Abstract][Full Text] [Related]
18. Complement activating properties of complexes containing rheumatoid factor in synovial fluids and sera from patients with rheumatoid arthritis.
Elson CJ; Carter SD; Cottrell BJ; Scott DG; Bacon PA; Wallington TB
Clin Exp Immunol; 1985 Feb; 59(2):285-92. PubMed ID: 3978872
[TBL] [Abstract][Full Text] [Related]
19. Terminal complement complexes and C1/C1 inhibitor complexes in autoimmune thyroid disease.
Weetman AP; Cohen SB; Oleesky DA; Morgan BP
Clin Exp Immunol; 1989 Jul; 77(1):25-30. PubMed ID: 2766576
[TBL] [Abstract][Full Text] [Related]
20. Relative contribution of contact and complement activation to inflammatory reactions in arthritic joints.
Abbink JJ; Kamp AM; Nuijens JH; Erenberg AJ; Swaak AJ; Hack CE
Ann Rheum Dis; 1992 Oct; 51(10):1123-8. PubMed ID: 1444625
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
